



PHARMACEUTICAL 2020











PHARMACEUTICAL 2020

Merck & Co. Inc. Rank 21 of 362



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 412% points. The greatest weakness of Merck & Co. Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 201%, being 503% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	27,483,000
Cost of Goods Sold	14,112,000
Intangible Assets	33,621,000
Liabilities, Current	22,220,000
Liabilities, Non-Current	0
Other Assets	8,240,000
Other Compr. Net Income	-582,000
Other Expenses	2,464,000
Other Liabilities	0
Other Net Income	0
Property and Equipment	15,053,000
Research and Development	9,872,000
Revenues	46,840,000
Selling, General and Administrative Expense	10,615,000

Output Variable	Value in 1000 USD
Assets	84,397,000
Liabilities	22,220,000
Expenses	37,063,000
Stockholders Equity	62,177,000
Net Income	9,777,000
Comprehensive Net Income	9,486,000
Economic Capital Ratio	201%

